Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients.

Advances in medical sciences - 1 Jan 2011

Jurczyk K, Laurans L, Karpińska E, Wawrzynowicz-Syczewska M, Parczewski M, Boroń-Kaczmarska A

Abstract excerpt

PURPOSE: Attempt to create simple practical algorithm for prospective assessment of PEG interferon/ribavirin related treatment response in individuals with chronic hepatitis C (CHC) basing on the risk factors defined prior to the treatment initiation. MATERIAL/METHODS: Retrospective assessment of 45 female and 39 male previously untreated CHC patients aged 20 to 73 years, with genotype 1, undergoing standard...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Mass Index
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Predictive Value of Tests

Share to Ribavirin

Source

Identifiers

PMID: 22130295
DOI: 10.2478/v10039-011-0056-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients.PMID 22130295Read ↗

[Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1].Semantic proximity Read ↗

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.Semantic proximity Read ↗

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.Semantic proximity Read ↗

A Multi-Biomarker Prediction Model Integrating Genetics, Hematological Indices, and Fibrosis Stage to Forecast Non-Response in HCV Genotype 4Semantic proximity Read ↗

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.Semantic proximity Read ↗

Association between risk factors, basal viral load, virus genotype and the degree of liver fibrosis with the response to the therapy in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Predictors of response to chronic hepatitis C treatment.Semantic proximity Read ↗

Assessment of HCV viral load, genotype, liver biomarkers and clinical symptoms: Developing a mathematical model for prediction of HCV loadSemantic proximity Read ↗

Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.Semantic proximity Read ↗

Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.Semantic proximity Read ↗

Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.